Brought to you by 
GSK, Regulus pick HCV as lead indication in new miRNA deal
23 Nov 2015
Executive Summary
In their second deal together, GlaxoSmithKline and Regulus Therapeutics (microRNA drug discovery) have agreed to develop and market microRNA drug candidates against miRNA122 for all therapeutic areas. The companies will first focus on hepatitis C.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK, Regulus pick HCV as lead indication in new miRNA deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice